Xplora's Q3 EBITDA of NOK72m was 59% above our NOK45m and 24% above consensus.
Redeye provides a research update following Isofol’s Q3 report.
* Sales SEK 57m (42m excl. one-off) vs. ABGSCe 73m * EBIT SEK 11m vs.
Eolus’ Q3 report showed strong net sales and cash flow, driven by the Centennial Flats milestone pay...
* Short-term credit facility of MSEK 10 * Three projects could materialise within six months * We ma...
EUZ's Q3 earnings recovery provides a firmer base for year-end delivery, with therapeutic isotopes o...
OHB's Q3 delivered further margin improvement on moderate output growth, with secured programmes and...
Tonies Q3 sales rose 28% yoy to € 180m. Figurines drove the quarter (+35% yoy to € 131m), and earlie...
MLP's expanding recurring fee base, higher interest income and pension reform opportunity support co...
Q3 oper. EBITDA +27.8% yoy to € 29m (17.1% margin), revenue +4.
Redeye updates on Embracer post Q2-results which were stronger than expected in both Fellowship and ...
SUS reported Q3 sales and EBIT below our expectations.
* Defence drives 53% growth and a 36% EBITDA margin * ‘27e: 25% growth, EBITDA margin rising to 30% ...
* SBBs soften negative CEPS revisions * Net acquisitions and continued buybacks on the cards * 2027e...
Redeye returns following AAC's Q3 report, which posted 32% y/y revenue growth, though supply chain b...
Redeye presents its preview for Paxman’s Q3 2026 report, due on November 20.
Redeye provides a research update following the Q3 report recently published by Alzinova.
Redeye views Q3 as a largely pre-announced quarter, with a soft margin that we flagged in our update...
* Sales up 2% y-o-y as a slow summer holds back volumes * Gross margin of 46%, the strongest in seve...
We reduce 2026E-28E CEPS by 2-4% and adjust our fair value range to SEK 11.